Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda
16-12-2015
Acorda hits back at Kyle Bass IPR
28-05-2015
Gustavo Frazao / Shutterstock.com
The Patent Trial and Appeal Board (PTAB) has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Patent Trial and Appeal Board; USPTO; PTAB; US Patent and Trademark Office; Kyle Bass; Coalition for Affordable Drugs; obvious; Acorda; Ampyra
